Drug Cocktail Offers Small Improvement To Breast Cancer Patients
A major clinical trial using a new anti-cancer medicine cocktail by the Swiss pharmaceutical giant Roche produced only a modest gain in survival, researchers said Monday. The study added pertuzumab (Perjeta) to the standard therapy, trastuzumab (Herceptin), in 4,805 women with HER2 positive breast cancer, an aggressive illness. “At an early follow up of three … Read more